Richmond Pharmacology highlights encouraging first-in-human results for Regeneron’s investigational RNAi therapy in MASLD

Richmond Pharmacology, a specialist early-phase clinical research organization, has announced encouraging results from a first-in-human clinical trial evaluating CIDEBsiRNA, an investigational RNA interference (RNAi) therapy developed by Regeneron Pharmaceuticals, Inc.

Continue ReadingRichmond Pharmacology highlights encouraging first-in-human results for Regeneron’s investigational RNAi therapy in MASLD

Orexo and SVF Vaccines collaborate to explore AmorphOX® formulation of LNP-mRNA vaccines

Orexo AB and SVF Vaccines AB today announced a research collaboration to investigate whether Orexo’s proprietary powder-based drug delivery technology, AmorphOX®, can be used to develop stable powder-based formulations of…

Continue ReadingOrexo and SVF Vaccines collaborate to explore AmorphOX® formulation of LNP-mRNA vaccines